Interleukin-6 prevents the initiation but enhances the progression of lung cancer

Cancer Research

Volumn 75, Issue 16, 2015, Pages 3209-3215

  Qu, Zhaoxia ^a,b   Sun, Fan ^a,b   Zhou, Jingjiao ^a,b   Li, Liwen ^a,b   Shapiro, Steven D ^a   Xiao, Gutian ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; INTERLEUKIN 10; INTERLEUKIN 6; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; STAT3 PROTEIN; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; CHEMOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; KRAS PROTEIN, HUMAN; KRAS2 PROTEIN, MOUSE; NOS2 PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN P21; RAS PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CLARA CELL; CONTROLLED STUDY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS EPITHELIUM CELL; LUNG ALVEOLUS MACROPHAGE; LUNG CANCER; LUNG CARCINOGENESIS; LUNG INJURY; LUNG LAVAGE; MOUSE; NONHUMAN; ONCOGENE K RAS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; DEFICIENCY; DISEASE COURSE; GENE EXPRESSION; GENETICS; HOMEOSTASIS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG; LUNG TUMOR; MACROPHAGE; METABOLISM; MUTATION; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHEMOKINES; CYCLIN D1; DISEASE PROGRESSION; GENE EXPRESSION; HOMEOSTASIS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; INTERLEUKIN-6; LUNG; LUNG NEOPLASMS; MACROPHAGES; MICE, KNOCKOUT; MUTATION; NITRIC OXIDE SYNTHASE TYPE II; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84942878342     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3042     Document Type: Article

References (20)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002;3:461-9.
3. Ancrile B, Lim KH, Counter CM.Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev 2007;21:1714-9.
4. Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 2014;26:54-74.
5. Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M, Chang H, et al. Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother 2004;53:786-92.
6. Koh E, Iizasa T, Yamaji H, Sekine Y, Hiroshima K, Yoshino I, et al. Significance of the correlation between the expression of interleukin 6 and clinical features in patients with non-small cell lung cancer. Int J Surg Pathol 2012;20:233-9.
7. Yeh HH, Lai WW, Chen HH, Liu HS, Su WC. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 2006;25:4300-9.
8. Huang F, Wang XL, Geng Y, Li MX. Evaluation of IL-6 level in serum and bronchoalveolar lavage fluid of patients with non-small cell lung cancer (NSCLC). Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2005;21:507-9.
9. Carpagnano GE, Resta O, Foschino-Barbaro MP, Gramiccioni E, Carpagnano F. Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer. Int J Biol Markers 2002;17:141-5.
10. Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, Chen YM, et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer 2013;132:1977-85.
11. Szczesny TJ, Slotwinski R, Stankiewicz A, Szczygiel B, Zaleska M, Kopacz M. Interleukin 6 and interleukin 1 receptor antagonist as early markers of complications after lung cancer surgery. Eur J Cardiothorac Surg 2007;31: 719-24.
12. Kita H, Shiraishi Y,Watanabe K, Suda K,Ohtsuka K, Koshiishi Y, et al. Does postoperative serum interleukin-6 influence early recurrence after curative pulmonary resection of lung cancer? Ann Thorac Cardiovasc Surg 2011;17: 454-60.
13. Wang XS, Shi Q, Williams LA, Mao L, Cleeland CS, Komaki RR, et al. Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun 2010;24:968-74.
14. Harada D, Takigawa N, Kiura K. The role of STAT3 in non-small cell lung cancer. Cancers (Basel) 2014;6:708-22.
15. Song L, Smith MA, Doshi P, Sasser K, Fulp W, Altiok S, et al. Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol 2014;9:974-82.
16. Zhou J,Qu Z, Yan S, Sun F, Whitsett JA, Shapiro SD, et al. Differential roles of STAT3 in the initiation and growth of lung cancer. Oncogene 2014 Oct 06. [Epub ahead of print].
17. Yan P, Fu J, Qu Z, Li S, Tanaka T, Grusby MJ, et al. PDLIM2 suppresses human T-cell leukemia virus type I Tax-mediated tumorigenesis by targeting Tax into the nuclear matrix for proteasomal degradation. Blood 2009;113:4370-80.
18. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007;110: 1911-28.
19. Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther 2011;11:1663-8.
20. Zhou B, Liu J, Wang ZM, Xi T. C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS One 2012;7:e43075.